Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer (VEOX)

Weill Cornell Medicine (WCM)

Status and phase: Completed; Phase 1

Conditions: Malignant Neoplasm of Cardio-esophageal Junction of Stomach; Esophageal Cancer

Treatments: Drug: Oxaliplatin; Drug: Epirubicin; Drug: Azacitidine; Drug: Capecitabine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01386346

VZ-ESOPH-PI-273 (Other Identifier)

1012011450

Details and patient eligibility

About

The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.

Full description

Currently patients with resectable (can be removed by surgery) esophageal cancer will receive chemotherapy before surgery to try to shrink the tumor before it is removed. This study will evaluate whether giving azacitidine before each cycle of chemotherapy to increase the shrinkage of the tumor prior to surgery is safe.

Azacitidine is currently approved by the Food and Drug Administration (FDA) for treatment of myelodysplastic syndrome (MDS). Azacitidine is not approved by the FDA for use in this study and is therefore considered investigational. Because azacitidine has not been given before in combination with epirubicin, oxaliplatin and capecitabine, we will also evaluate the safety and tolerability of azacitidine and find out what dose of azacitidine is safe to give with this chemotherapy.

Enrollment: 12 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed adenocarcinoma or poorly differentiated carcinoma of the intrathoracic esophagus or gastroesophageal junction (GEJ) and deemed resectable by the thoracic surgeon.
• No prior chemotherapy for esophageal or GEJ cancer.
• ECOG Performance status 0-2.
• Adequate bone marrow, kidney and liver function.
• Ability to understand and the willingness to sign a written informed consent document.
• Subjects of child-bearing potential must agree to use effective means of contraception (men and women).
• Prior malignancy is acceptable if the subject is considered to be cured. In most cases this will mean a 5-year disease-free period.

Exclusion criteria

• Patients with cervical esophageal cancer or esophageal cancer with squamous cell carcinoma morphology.
• Subjects receiving any other investigational agent or received prior chemotherapy for esophageal or GEJ cancer.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to azacitidine, epirubicin, oxaliplatin, capecitabine and mannitol.
• New York Heart Association (NYHA) Grade II or greater congestive heart failure.
• History of myocardial infarction or unstable angina within 6 months prior to study enrollment.
• Pregnant (positive pregnancy test) or lactating women.
• Patients with active infection, serious inter-current medical conditions.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

All subjects

Experimental group

Description:

Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles. Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2

Treatment:

Drug: Capecitabine

Drug: Azacitidine

Drug: Epirubicin

Drug: Oxaliplatin